期刊
TRENDS IN MOLECULAR MEDICINE
卷 18, 期 1, 页码 27-35出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2011.08.001
关键词
-
资金
- National Institutes of Health [K24 CA149202]
- Melanoma Research Alliance
- American Skin Association
- Massachusetts General Hospital
Metastatic melanoma is a highly lethal type of skin cancer and is often refractory to all traditional chemotherapeutic agents. Key insights into the genetic make-up of melanoma tumors have led to the development of promising targeted agents. An activated RAS pathway, anchored by oncogenic BRAF, appears to be the central motor driving melanoma proliferation. Although recent clinical trials have brought enormous hope to patients with melanoma, adverse effects and novel escape mechanisms of these inhibitors have already emerged. Definition of the limits of the first successful targeted therapies will provide the basis for further advances in management of disseminated melanoma. In this review, the current state of targeted therapy for melanoma is discussed, including the potent BRAF(V600E) inhibitor vemurafenib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据